Outcomes of Pelvic Exenteration for Rectal Cancer
Author Information
Author(s): Maudsley J, Clifford RE, Aziz O, Sutton PA
Primary Institution: Colorectal and Peritoneal Oncology Centre, Christie NHS Foundation Trust, UK
Hypothesis
What are the long-term oncosurgical and quality of life outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer?
Conclusion
Pelvic exenteration is safe with a good chance of R0 resection and acceptable mortality rates, but high morbidity rates highlight the need for shared decision-making.
Supporting Evidence
- 25 papers reported outcomes for 5,489 patients.
- R0 resection rates ranged from 23.2% to 98.4%.
- Overall morbidity rates were between 17.8% and 87.0%.
- The median survival ranged from 12.5 to 140.0 months.
- Only four studies reported quality of life outcomes.
Takeaway
Pelvic exenteration is a surgery for advanced rectal cancer that can help patients live longer, but it can also cause a lot of problems afterward.
Methodology
A systematic review of studies reporting long-term outcomes following pelvic exenteration for rectal cancer, adhering to PRISMA guidelines.
Potential Biases
All studies included in the review had a high risk of bias.
Limitations
High risk of bias in included studies and significant heterogeneity in reported outcomes.
Participant Demographics
Median age ranged from 45.0 to 72.5 years; predominantly male participants (57%).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website